Nasus Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on February 11, 2026, by Nasus Pharma Ltd., a foreign private issuer based in Tel Aviv, Israel, reports on a private placement financing transaction entered into on February 10, 2026. The filing details the terms of a securities purchase agreement with institutional and accredited investors.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Expected to be $15.0 million.
- Securities Issued: 2,695,425 ordinary shares and accompanying warrants to purchase an equal number of shares.
- Purchase Price: $5.565 per share and accompanying warrant.
- Warrant Terms: Exercise price of $6.53 per share; immediately exercisable; expiration upon the earlier of two years from issuance or 30 trading days following the announcement of top-line results for the NS002 Pivotal Study.
- Transaction Costs: A cash placement fee of 6.0% of gross proceeds ($900,000) plus reimbursement of expenses up to $55,000.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for historical revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes and Use of Proceeds
The primary material change is the capital raise intended to extend the company's runway. The net proceeds, combined with existing cash and short-term investments, will be used to:
- Advance the pivotal clinical development of NS002 for anaphylaxis treatment.
- Initiate first-in-human studies for other pipeline products.
- Support working capital and general corporate purposes.
Outlook, Risks, and Contingencies
The closing of the offering is expected on or about February 12, 2026, subject to customary conditions. The company has entered into a registration rights agreement to facilitate the resale of the securities. The filing includes a Safe Harbor statement noting that forward-looking statements regarding proceeds, use of funds, and closing dates are subject to uncertainties. Specific risks are referenced in the company's prospectus dated August 12, 2025, including the uncertainty of clinical trial results.
Investor Verification Checklist
- Verify the actual closing date and confirmation of the $15.0 million gross proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and investor rights.
- Confirm the current cash balance and burn rate to assess the runway extension provided by this financing.
- Monitor the timeline for the NS002 Pivotal Study top-line results, as this triggers warrant expiration.
- Check for any subsequent filings regarding the registration statement for the resale of shares.